MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors

Cancer Letters

Volumn 102, Issue 1-2, 1996, Pages 7-16

  Kavallaris, Maria ^a   Leary, Jennifer A ^b   Barrett, Julie A ^c   Friedlander, Michael L ^b,c  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

MDR1; MRP; Ovarian tumor

Indexed keywords

ARTICLE; CANCER GENETICS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0029993705     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3835(96)04143-2     Document Type: Article

References (33)

1. de Souza, P.L. and Friedlander, M.L. (1992) Prognostic factors in ovarian cancer. Haematol. Oncol. Clin. N. Am., 6, 761-781.
2. Friedlander, M.L. Drug resistance in ovarian cancer. (1992) Int. J. Gynecol. Oncol., Suppl. 1, 2-10.
3. Johnson, S.W., Ozols, R.E. and Hamilton, T.C. (1993) Mechanisms of drug resistance in ovarian cancer. Cancer, 71, 644-649.
4. Izquierdo, M.A., Vanderzee, A.G.J., Vermorken, J.B., Vandervalk, P., Belien, J.A.M., Giaccone, G., Scheffer, G.L., Flens, M.J., Pinedo, H.M., Kenemans, P., Meijer, C.J.L.M., Devries, E.E.G. and Scheper, R.J. (1995) Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma. J. Natl. Cancer Inst., 87, 1230-1237.
5. Roninson, I.B. (Editor) (1991) Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. Plenum, New York.
6. Bell, D.R., Gerlach, J.H., Kartner, N., Buick, R.N. and Ling, V. (1985) Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J. Clin. Oncol., 3, 311-315.
7. Louie, K., Ozols, R., Myers, C., Ostechega, Y., Jenkins, J., Howser, D. and Young, R. (1986) Long-term results of cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. J. Clin. Oncol., 4, 1579-1585.
8. Bourhis, J., Goldstein, L.J., Riou, G., Pastan, I., Gottesman, M.M. and Benard, J. (1989) Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res., 49, 5062-5065.
9. Cole, S.P.C., Bhardwaj, G., Gerlach, J.H., Mackie, J.E., Grant, C.E., Almquist, K.C., Stewart, A.J., Kurz, E.U., Duncan, A.M.V. and Deeley, R.G. (1992) Overexpression of a transport gene in a multidrug-resistant human lung cancer cell line. Science (Washington DC), 258, 1650-1654.
10. Barrand, M.A., Heppell-Parton, A.C., Wright, K.A., Rabbitts, P.M. and Twentyman, P.R. (1994) A 190-kilodalton protein over-expressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. J. Natl. Cancer Inst., 86, 110-117.
11. Zaman, G.J.R., Flens, M.J., van Leusden, M.R., de Haas, M., Mülder, H.S., Lankelma, J., Pinedo, H.M., Scheper, R.J., Baas, F., Broxterman, H.J. and Borst, P. (1994) The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA, 91, 8822-8826.
12. Kruh, G.D., Chan, A., Myers, K., Gaughan, K., Miki, T. and Aaronson, S.A. (1994) Expression complimentary DNA library transfer establishes mrp as a multidrug resistance gene. Cancer Res., 54, 1649-1652.
13. Burger, H., Nooter, K., Zaman, G.J.R., Sonneveld, P., van Wingerden, K.E., Oostrum, R.G. and Stoter, G. (1994) Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukaemias. Leukaemia, 8, 990-997.
14. Beck, J., Niethammer, D. and Gekeler, V. (1994) High mdrl- and mrp-, but low topoisomerase Ha-gene expression in B-cell chronic lymphocytic leukaemias. Cancer Lett., 86, 135-142.
15. Hart, S.M., Ganeshaguru, K., Hoffbrand, A.V., Prentice, H.G. and Mehta, A.B. (1994) Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia. Leukaemia, 8, 2163-2168.
16. Schneider, E., Cowan, K.H., Bader, H., Toomey, S., Schwanz, G.N., Karp, J.E., Burke, P.J. and Kaufmann, S.H. (1995) Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood, 85, 186-193.
17. Schuurhuis, G.J., Broxterman, H.J., Ossenkoppele, G.J., Baak, J.P.A., Eekman, C.A., Kuiper, C.M., Feller, N., van Heijningen, T.H.M., Klumper, E., Pieters, R., Lankelma, J. and Pinedo, H.M. (1995) Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MDR1 together with 1-b-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin. Cancer Res., 1, 81-93.
18. Bordow, S.B., Haber, M., Madafiglio, J., Cheung, B., Marshall, G.M. and Norris, M.D. (1994) Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res., 54, 5036-5040.
19. Sugawara, I., Masunaga, A., Itoyama, S., Sumizawa, T., Akiyama, S. and Yamashita, T. (1995) Expression of multidrug resistance-associated protein (MRP) in thyroid cancers. Cancer Lett., 95, 135-138.
20. Noonan, K.E., Beck, C., Holzmayer, T.A., Chin, J.E., Wunder, J.S., Andrulis, I.L., Gazdar, A.F., Willman, C.L., Griffith, B., Von Hoff, D.D. and Roninson, I.B. (1990) Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc. Natl. Acad. Sci. USA, 87, 7160-7164.
21. Foley, G.E., Lazarus, H., Farber, S., Uzman, B.G., Boone, B.A. and McCarthy, R.E. (1965) Continuous culture of peripheral blood of a child with acute leukaemia. Cancer, 18, 522-529.
22. Haber, M., Morris, M.D., Kavallaris, M., Bell, D.R., Davey, R.A., White, L. and Stewart, B.W. (1989) Atypical multidrug resistance in a therapy-induced drug-resistant human leukaemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein. Cancer Res., 49, 5281-5287.
23. Shen, D.-W., Cardarelli, C., Huang, J., Cornwell, M., Richert, N., Ishii, S., Pastan, I. and Gottesman, M. (1986) Multiple drug-resistant human KB carcinoma cells independently selected for high level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J. Biol. Chem., 261, 7762-7770.
24. Schneider, E., Horton, J.K., Yang, C-H., Nakagawa, M. and Cowan, K.H. (1994) Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res., 54, 152-158.
25. van Haaften-Day, C., Russell, P. and Brammah-Carr, S. (1990) Two Homologous mixed mullerian tumor lines of the ovary and their characteristics. Cancer, 65, 1753-1761.
26. Zaman, G.J.R., Versantvoort, C.H.M., Smit, J.J.M., Eijdems, E.W.H.M., de Haas, M., Smith, A.J., Broxterman, H.J., Mulder, N.H., de Vries, E.G.E., Baas, F. and Borst, P. (1993) Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res., 53, 1747-1750.
27. [27 Grant, C.E., Valdimarsson, G., Hipfner, D.R., Almquist, K.C., Cole, S.P.C. and Deeley, R.G. (1994) Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res., 54, 357-361.
28. Trimble, E.L., Adams, J.D., Vena, D., Hawkins, M.J., Friedman, M.A., Fisherman, J.S., Christian, M.C., Canetta, R., Onetto, N., Hayn, R. and Arbuck, S.G. (1993) Paclitaxel for platinum refractory ovarian cancer: Results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103. J. Clin. Oncol., 11, 2405-2410.
29. Müller, M., Meijer, C., Zaman, G.J.R., Borst, P., Scheper, R.J., Mulder, N.H., De Vries, E.G.E. and Jansen, P.L.M. (1994) Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. USA, 91, 13033-13037.
30. Jedlitschky, G., Leier, I., Buchholz, U., Center, M. and Keppler, D. (1994) ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res., 54, 4833-4836.
31. 4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem. Biophys. Res. Commun., 208, 345-352.
32. Bailey, H.H., Wilding, G., Tutsch, K.D., Arzoomanian, R.Z., Alberti, D., Feierabend, C. and Mulchahy, R.T. (1994) A phase I trial of L-S, R-butathionine sulfoximine (BSO) given as a 24-48 hour continuous infusion (CI) with IV melphalan (L-PAM). Proc. Am. Soc. Clin. Oncol, 13th Ann. Meeting, pp. 135.
33. Holzmayer, T.A., Hilsenbeck, S., Von Hoff, D.D. and Roninson, I.B. (1992) Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J. Natl. Cancer Inst., 84, 1486-1491.